Nycomed Amersham Imaging has announced favorable results from a 12-year study of patients receiving treatment with its OncoSeed brachytherapy iodine-125 seeds. In research presented at the American Urological Association meeting in Atlanta, a follow-up study of early-stage prostate cancer patients treated with OncoSeed demonstrated disease-free survival rates comparable to those reported for patients undergoing radical prostatectomy, according to the Princeton, NJ-based firm. The research also matches data from a 10-year OncoSeed study published in 1998, according to Nycomed Amersham.
By AuntMinnie.com staff writers
May 4, 2000
Copyright © 2000 AuntMinnie.com
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
